Simplex Trading’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Simplex Trading’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-640	Closed	–	–	11046
2022 Q3	$0	Buy	640 +600	+1,500%	+$237	﹤0.01%	11359
2022 Q2	$0	Buy	+40	New	+$20	﹤0.01%	11601
2022 Q1	–	Sell	-9,686	Closed	-$10.6K	–	11816
2021 Q4	$22K	Buy	9,686 +8,865	+1,080%	+$30K	﹤0.01%	8283
2021 Q3	$3K	Hold	821	–	–	﹤0.01%	9486
2021 Q2	$3K	Buy	+821	New	+$4.18K	﹤0.01%	9673

Simplex Trading's LOGC Position: Q4 2022 in Review

Simplex Trading sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 640 shares.

Simplex Trading first reported a position in LOGC in Q2 2021 and held it in 5 quarters. The position peaked at $22K in Q4 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Simplex Trading reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Simplex Trading sold 640 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022.
Simplex Trading first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Simplex Trading's LogicBio Therapeutics, Inc. Common Stock position peaked at $22K in Q4 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Simplex Trading's 13F filing for Q4 2022, filed 2 Feb 2023.